BioWorld

May 16, 2002

View Archived Issues

Tranzyme Enters QBI Deal, Targets Neurosensory Drugs

Read More

Hyseq, BASF To Finish Deal Early; Hyseq Cutting Employees

Read More

Second-Generation LongSAGE' Strategists Say 15,000 Genes In Human Genome Still Uncounted

Read More

Nexell's Board OKs Orderly Wind-Down' Of Operations

Read More

Other News To Note

Read More

Corixa Wants Dispute Resolution For Bexxar Through FDAMA

Corixa Corp. said it is requesting an appeal of the FDA's complete review letter questioning the net clinical benefit and safety of the company's lead cancer product, known as Bexxar. (BioWorld Today) Read More